Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02324725 · ClinicalTrials.gov registry record · Phase 4
Biomarkers of Injectable Extended Release Naltrexone Treatment
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT02324725: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT02324725 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02324725, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests probing various aspects of personality, memory, reward processing and attention.
Interventions
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-10 |
| Est. Completion | 2021-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02324725
The ClinicalTrials.gov registry entry for NCT02324725 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Naltrexone is the first listed.
NCT02324725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02324725 about?
NCT02324725 is a clinical study titled "Biomarkers of Injectable Extended Release Naltrexone Treatment". This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests pro...
What is the current status of trial NCT02324725?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2011-10. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02324725?
The interventions under investigation include: Naltrexone (DRUG).
Who is sponsoring clinical trial NCT02324725?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.